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Abstract  Recent  interest  in  the  coadministration  of  approved  pharmaceutical  agents  has
resulted in  a  wealth  of  emerging  data  on  the  safety  and  efﬁcacy  of  dual  pharmacological  treat-
ment for  lower  urinary  tract  symptoms  (LUTS).  Much  evidence  supports  the  coadministration  of
-blockers with  5-alpha-reductase  inhibitors  (5-ARIs)  in  patients  at  risk  for  clinical  progression.
The use  of  phosphodiesterase-5  inhibitors  (PDE5Is)  in  combination  with  5-ARIs  has  also  demon-
strated a  good  safety  and  efﬁcacy  proﬁle,  providing  early  symptomatic  relief  and  reduction  of
sexual side  effects  associated  with  5-ARI  use,  although  longer-term  studies  are  needed.  Studies
investigating  the  combination  of  PDE5Is  with  -blockers  have  shown  additive  effects  on  each
of the  individual  agents  with  respect  to  the  International  Prostate  Symptom  Score  (IPSS)  and
the International  Index  of  Erectile  Function  (IIEF),  which  holds  promise  for  patients  who  have
shown a  poor  response  to  monotherapy.  The  coadministration  of  -blockers  and  antimuscarinic
agents provides  an  alternative  for  treatment  of  storage  symptoms  in  patients  who  have  failed
to respond  to  monotherapy.  This  review  aims  to  summarize  and  comment  on  available  evidence
regarding the  safety  and  efﬁcacy  of  combination  treatment  for  LUTS.
© 2016  Published  by  Masson  Doyma  Me´xico  S.A.  on  behalf  of  Sociedad  Mexicana  de  Urolog´ıa.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
PALABRAS  CLAVE
Síntomas  del  tracto
Combinación  de  terapias  para  el  tratamiento  de  los  síntomas  del  tracto  urinario
inferior  en  hombresurinario  inferior;
Terapia  de
combinación;
Inhibidores  de  la
5-reductasa;
Resumen  El  reciente  interés  en  la  administración  conjunta  de  agentes  farmacéuticos  aproba-
dos ha  dado  lugar  a  una  gran  cantidad  de  nuevos  datos  sobre  la  seguridad  y  eﬁcacia  del
tratamiento  dual  farmacológico  para  los  síntomas  del  tracto  urinario  inferior.  La  evidencia  cien-
tíﬁca apoya  la  co-administración  de  bloqueadores  alfa  con  inhibidores  de  la  5-alfa-reductasa
(5-ARI) en  pacientes  con  riesgo  de  progresión  clínica.
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fosfodiesterasa  5;
Antimuscarínicos
El  uso  de  inhibidores  de  la  fosfodiesterasa-5  en  combinación  con  5-ARI  también  ha  demostrado
un adecuado  perﬁl  de  seguridad  y  eﬁcacia,  proporcionando  mejoría  sintomática  y  reducción  de
los efectos  sexuales  secundarios  asociados  al  uso  de  5-ARI,  aunque  se  necesitan  estudios  a  largo
plazo. Los  estudios  de  combinación  de  inhibidores  de  la  fosfodiesterasa-5  con  bloqueadores
alfa han  mostrado  efectos  aditivos  con  respecto  al  Índice  Internacional  de  Síntomas  Prostáticos
(IPSS) y  al  Índice  Internacional  de  Función  Eréctil  (IIEF)  sobre  cualquiera  de  los  agentes  en
forma individual,  lo  que  mantiene  la  eﬁcacia  clínica  para  los  pacientes  que  han  mostrado  una
pobre respuesta  a  la  monoterapia.  Además  la  coadministración  de  bloqueadores  alfa  y  agentes
antimuscarínicos  ofrece  una  alternativa  para  el  tratamiento  de  los  síntomas  de  almacenamiento
en pacientes  que  no  han  respondido  a  la  monoterapia.  Esta  revisión  tiene  como  objetivo  resumir
y comentar  la  evidencia  disponible  sobre  la  seguridad  y  eﬁcacia  del  tratamiento  combinado  para
síntomas del  tracto  urinario  inferior.
© 2016  Publicado  por  Masson  Doyma  Me´xico  S.A.  en  nombre  de  Sociedad  Mexicana  de  Urolog´ıa.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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zosin  dose  was  1  mg  QD  for  the  ﬁrst  week,  increasing  toIntroduction
The  causal  link  between  the  prostate  and  lower  urinary
tract  symptoms  (LUTS)  has  come  into  question  during  the
past  decade,  and  the  correlation  between  prostate  size  and
symptoms,  measured  by  the  International  Prostate  Symp-
tom  Score  (IPSS),  has  been  shown  to  be  weak.1 Because  of
these  recent  ﬁndings  and  because  patients  seek  help  for
LUTS  rather  than  for  a  particular  underlying  contributing
factor  such  as  benign  prostatic  hyperplasia  (BPH)  or  benign
prostatic  obstruction  (BPO),  more  recent  updates  to  inter-
national  clinical  management  guidelines  are  now  written
from  the  perspective  of  men  who  suffer  from  LUTS,  which
incorporates  a  variety  of  bladder  storage,  voiding,  and/or
post-micturition  symptoms.2 Storage  symptoms  typically
include  daytime  urinary  frequency,  nocturia,  urgency,  or  uri-
nary  incontinence;  voiding  symptoms  include  slow  stream,
splitting  or  spraying,  intermittency,  hesitancy,  straining,  and
terminal  dribble;  and  post-micturition  symptoms  refer  to
the  sensation  of  incomplete  emptying  or  post-micturition
dribble.
The  evolving  understanding  about  factors  that  may
contribute  to  LUTS  has  led  to  increased  interest  in  the  com-
bination  of  existing  treatment  approaches,  so  that  multiple
modes  of  action  can  be  used  to  best  manage  symptoms.
The  mainstay  of  current  treatment  approaches  for  LUTS
includes  the  four  main  drug  classes  used  as  monotherapies,
and  the  combination  of  5-reductase  inhibitors  (5-ARIs)  with
-adrenoceptor  antagonists  (-blockers).2 The  -blockers
are  traditionally  the  ﬁrst-line  treatment  for  managing  signs
or  symptoms  of  BPH/LUTS,  and  this  class  of  agent  includes
alfuzosin,  doxazosin,  silodosin,  tamsulosin,  and  terazosin.
The  5-ARIs  are  used  to  manage  benign  prostatic  enlargement
(BPE),  and  the  two  key  agents  are  dutasteride  and  ﬁnas-
teride.  Antimuscarinic  agents  are  primarily  used  to  treat
overactive  bladder  (OAB)  and  other  storage  symptoms,  and
the  most  common  in  this  class  include  oxybutynin,  propiver-
ine,  solifenacin,  and  tolteroidine.  The  phosphodiesterase-5
inhibitors  (PDE5Is)  are  used  for  treating  the  signs  or  symp-
toms  or  BPH  with  or  without  erectile  dysfunction.  The  only
agent  licensed  for  this  indication  is  tadalaﬁl;  the  other
PDE5Is,  vardenaﬁl  and  sildenaﬁl,  are  licensed  as  on-demand
erectile  dysfunction  agents.
4
5
tThe  Multinational  Survey  of  the  Aging  Male-7  reported
hat  among  men  ≥50  years  of  age,  43%  with  mild  LUTS,
5.8%  with  moderate  LUTS,  and  82.5%  with  severe  LUTS,
lso  suffer  from  erectile  problems.3 This  multinational  sur-
ey  concluded  that  sexual  activity  is  common  in  a  majority
f  men  ≥50  years  of  age  and  is  an  important  component
f  overall  quality  of  life,  highlighting  the  need  to  consider
exual  issues  in  the  management  of  patients  with  LUTS.3
ecause  of  the  positive  impact  of  PDE5Is  on  erectile  dysfunc-
ion,  there  has  been  considerable  interest  in  therapeutic
egimens  that  include  this  class  of  agent.  The  purpose  of
his  article  is  to  review  evidence  on  the  efﬁcacy  and  safety
f  dual  pharmacological  treatment  for  LUTS,  with  the  aim
f  making  evidence-based  decisions  about  the  suitability  of
atients  with  particular  symptoms  or  risk  proﬁles  for  differ-
nt  types  of  combination  therapy.
-Blocker/5-ARI combination therapy
his  is  the  most  widely  investigated  combination  therapy
or  LUTS,  with  many  clinical  trials  building  the  evidence
or  efﬁcacy  of  treatment  combinations  in  this  class.  The
ey  initial  studies  were  the  Prospective  European  Doxa-
osin  and  Combination  Therapy  (PREDICT)  study,4 which
nvestigated  ﬁnasteride  with  terazosin,  the  Alfuzosin  Finas-
eride  (ALFIN)  study,5 which  investigated  ﬁnasteride  with
lfuzosin,  and  the  Veterans  Affairs  Cooperative  (VA-COOP)
tudy,6 which  investigated  ﬁnasteride  with  doxazosin,  for
 or  12  months.  All  three  studies  reported  signiﬁcantly
mproved  symptom  scores  (American  Urological  Association
ymptom  score  [AUA-SS]  or  IPSS)  in  the  combination  therapy
roups  compared  with  the  baseline  and  5-ARI  monotherapy
roups,  with  reductions  from  the  baseline  between  6.1  and
.5  points.4--6
Three  studies  lasted  longer  than  1  year,  the  ﬁrst  of  which
as  the  Medical  Therapy  of  Prostatic  Symptoms  (MTOPS)
tudy.  It  investigated  the  long-term  effects  of  placebo,
oxazosin  1  to  8  mg  once  daily  [QD]  monotherapy  (doxa- mg  or  8  mg  QD,  depending  on  tolerability),  ﬁnasteride
 mg  QD  monotherapy,  and  ﬁnasteride/doxazosin  combina-
ion  therapy  on  BPH  clinical  progression  in  3047  symptomatic
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atients,  with  a  mean  follow-up  of  4.5  years.7 Risk  for
verall  clinical  progression,  deﬁned  as  an  increase  above
he  baseline  of  at  least  4  points  in  the  AUA-SS,  acute  uri-
ary  retention,  urinary  incontinence,  renal  insufﬁciency,  or
ecurrent  urinary  tract  infection,  was  signiﬁcantly  reduced
ith  the  doxazosin  (39%  risk  reduction;  p  < 0.001)  and
nasteride  (34%  risk  reduction;  p  =  0.002)  monotherapies
ompared  with  placebo,  and  the  risk  reduction  was  signi-
cantly  greater  with  the  combination  therapy  (p  <  0.001)
han  with  either  of  the  agents  alone  (p  <  0.001  for  both)
hen  compared  with  placebo.7 Similarly,  the  risk  for  acute
rinary  retention  and  need  for  invasive  therapy  were  sig-
iﬁcantly  reduced  with  the  combination  therapy  (p  <  0.001)
nd  ﬁnasteride  monotherapy  (p  <  0.001),  but  not  with  doxa-
osin  monotherapy.7 The  most  common  adverse  events  with
oxazosin  monotherapy  compared  with  placebo  were  dizzi-
ess,  postural  hypotension,  and  asthenia;  with  ﬁnasteride
onotherapy,  they  were  erectile  dysfunction,  decreased
ibido,  and  abnormal  ejaculation.  The  adverse  events  with
oxazosin/ﬁnasteride  combination  therapy  were  similar  to
hose  with  each  drug  alone,  with  the  exception  of  abnor-
al  ejaculation,  peripheral  edema,  and  dyspnea  --  all
f  which  occurred  more  frequently  in  patients  receiving
he  combination  therapy.  The  rate  per  100  person-years
f  follow-up  of  erectile  dysfunction  was  4.53  with  ﬁnas-
eride  monotherapy  and  5.11  with  the  combination  therapy;
oth  rates  were  signiﬁcantly  higher  than  the  rate  with
lacebo.7
Another  large-scale,  long-term  follow-up  study,  the
ombination  of  Avodart  and  Tamsulosin  (CombAT)  study,
nvestigated  the  efﬁcacy  and  safety  of  dutasteride  0.5  mg
D  monotherapy,  tamsulosin  0.4  mg  QD  monotherapy,  and
he  dutasteride/tamsulosin  combination  therapy  in  reducing
he  relative  risk  for  acute  urinary  retention  (AUR),  BPH-
elated  surgery,  and  BPH  clinical  progression  over  4  years
n  4844  men  at  increased  risk  for  progression.8,9 The  4-year
ollow-up  results  showed  that  the  combination  therapy  was
igniﬁcantly  superior  to  tamsulosin  monotherapy  at  reducing
he  relative  risk  for  AUR  and  BPH-related  surgery  (p  <  0.001).
t  was  not  superior  to  dutasteride  monotherapy.  The  combi-
ation  therapy  was,  however,  also  signiﬁcantly  superior  to
oth  monotherapies  at  reducing  the  relative  risk  for  BPH
linical  progression  (p  <  0.001  for  both).9 An  IPSS  reduction
f  6.3  points  was  reported  for  the  combination  therapy
ersus  3.8  points  for  tamsulosin  (p  <  0.001)  and  5.3  points
or  dutasteride  (p  <  0.001).  Superiority  of  the  combination
herapy  versus  tamsulosin  from  month  9  and  versus  dutas-
eride  from  month  3  was  observed  and  was  maintained  for
he  study  duration  (p  <  0.001  for  all  comparisons).9 There
ere  signiﬁcantly  more  drug-related  adverse  events  in  the
ombination  group.  However,  the  withdrawal  rates  due  to
rug-related  adverse  events  were  similar  across  the  three
reatment  groups  (6%  in  the  combination  group  and  4%  in
he  dutasteride  and  tamsulosin  groups).  Erectile  dysfunc-
ion  occurred  in  5%  of  the  subjects  in  the  tamsulosin  group,
%  in  the  dutasteride  group,  and  9%  in  the  combination
herapy  group.  Although  there  was  no  difference  in  overall
ardiovascular  events  across  treatment  groups,  the  inci-
ence  of  the  composite  term  ‘‘cardiac  failure’’  was  higher  in
he  combination  (0.9%)  and  tamsulosin  monotherapy  groups
0.6%)  compared  with  the  dutasteride  monotherapy  group
0.2%).9
S
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Most  recently,  the  CONDUCT  study  investigated  the
rst-line  treatment  of  men  with  BPH  with  a  ﬁxed-dose  com-
ination  of  dutasteride  0.5  mg  and  tamsulosin  0.4  mg  QD
ompared  with  watchful  waiting  and  initiation  of  tamsulosin
.4  mg  QD  if  symptoms  did  not  improve.10 All  patients  were
iven  lifestyle  advice  about  symptom  management.  The
hange  in  the  IPSS  after  24  months  of  follow-up  was  signiﬁ-
antly  greater  in  the  combination  group  than  in  the  watchful
aiting/tamsulosin  group  (−5.4  vs.  −3.6  points;  p  <  0.001),
nd  the  combination  therapy  signiﬁcantly  reduced  the  rel-
tive  risk  for  BPH  progression  by  43.1%  compared  with
atchful  waiting/tamsulosin  (p  <  0.001).10 The  most  com-
only  reported  adverse  events  across  the  combination
herapy  and  tamsulosin  monotherapy  groups  were  erectile
ysfunction,  which  occurred  in  8%  and  5%,  and  retrograde
jaculation,  which  occurred  in  0%  and  4%,  respectively.
atients  in  the  combination  therapy  group  also  reported  loss
f  libido  and  ejaculation  disorder  (2%  for  each,  but  neither
as  reported  in  the  watchful  waiting/tamsulosin  group).10
The  long-term  follow-up  results  from  the  MTOPS,
ombAT,  and  CONDUCT  studies  are  considered  the  most
elevant  due  to  the  long-term  effect  of  the  5-ARI  drug
lass.  However,  the  patient  populations  were  slightly  dif-
erent  among  the  studies:  the  MTOPS  study  included  men
ith  LUTS,  regardless  of  prostate  volume  or  symptom  score,
hereas  the  CombAT  study  included  those  ≥50  years  of
ge  with  prostate  volumes  ≥30  mL,  IPSS  ≥12  and  prostate-
peciﬁc  antigen  (PSA)  1.5--10  ng/mL,  and  the  CONDUCT
tudy  enrolled  subjects  with  prostate  volumes  ≥30  mL,  IPSS
--19,  and  total  serum  PSA  ≥  1.5  ng/mL.7,9,10 The  results  from
hese  long-term  studies  favored  the  combination  therapy
ver  either  of  the  monotherapies,  in  terms  of  the  AUA-SS  and
PSS,  as  well  as  maximal  ﬂow  rate  (Qmax)  and  delay  in  disease
rogression.  It  is  not  known  whether  the  observed  differ-
nce  in  clinical  outcomes  persists  for  longer  than  a  4-year
eriod.  In  addition,  although  5-ARI  monotherapy  has  a  mod-
st  effect  on  sexual  function  (penile  erection,  ejaculation,
nd  sexual  desire)  in  men  with  LUTS,  the  MTOPS  and  CombAT
tudies  found  that  when  adding  select  -blockers,  the  sex-
al  side  effects  on  ejaculation  dysfunction  were  additive.11
imilarly,  the  CONDUCT  study  reported  increased  sexual  side
ffects  (erectile  dysfunction,  retrograde  ejaculation,  loss
f  libido)  with  the  combination  therapy  compared  with  the
atchful  waiting/tamsulosin  monotherapy  treatment.10
linical  management  implications
he  primary  use  of  this  treatment  combination  seems  to
e  in  patients  with  moderate  to  severe  symptoms  (IPSS  >  7
r  AUA-SS  >  8)  who  show  risk  factors  for  clinical  progres-
ion,  although  much  of  the  long-term  data  have  come  from
tudies  that  included  only  subjects  with  large  prostate
olumes  (≥30  mL).  The  most  recent  American  Urological
ssociation  (AUA)  guideline  (2010)  advises  that  the  -
locker/5-ARI  combination  is  effective  for  the  treatment
f  LUTS  with  demonstrable  prostatic  enlargement  based
n  volume  measurement  or  PSA  level  as  a  proxy  for  vol-imilarly,  the  2013  European  Association  of  Urology  (EAU)
uidelines  also  recommend  this  treatment  combination  in
ubjects  with  enlarged  prostates2 and  the  2010  National
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Institute  for  Health  and  Clinical  Excellence  (NICE)  guide-
lines  suggest  offering  this  treatment  combination  to  men
with  large  prostates  or  PSA  >  1.4  ng/mL  and  who  are  con-
sidered  at  risk  for  progression  due  to,  for  example,  older
age.13
The  results  of  three  studies  that  examined  withdrawal  of
the  -blocker  after  initial  combination  therapy  indicate  that
when  this  treatment  combination  is  used,  the  -blocker  may
be  discontinued  once  the  maximum  effect  of  the  5-ARI  has
been  achieved  in  patients  with  mild  to  moderate  symptoms,
usually  after  6--12  months  of  combination  treatment.14--16 In
the  Symptom  Management  After  Reducing  Therapy  (SMART-
1)  study,  84%  of  men  with  baseline  IPSS  <  20  changed  to
5-ARI  monotherapy  after  24  weeks  without  noticeable  dete-
rioration  in  symptoms.  However,  42.5%  of  men  with  severe
baseline  symptoms  (IPSS  ≥  20)  reported  worsening  of  symp-
toms  after  withdrawal  of  the  -blocker.14 Rates  of  sexual
side  effects  were  similar  between  the  treatment  groups.  In
the  group  that  received  combination  therapy  for  36  weeks,
7%  experienced  ejaculation  disorders,  4%  decreased  libido,
and  5%  erectile  dysfunction;  in  the  group  that  switched
from  combination  therapy  to  dutasteride  monotherapy,  7%
experienced  ejaculation  disorders,  6%  decreased  libido,  and
2%  erectile  dysfunction.14 A  more  recent  study  of  103  BPH
patients  who  had  been  on  -blocker/dutasteride  combina-
tion  therapy  for  12  months  and  were  then  randomized  to
either  continuation  of  combination  therapy  or  withdrawal
of  the  -blocker,  showed  that  89%  of  patients  with  IPSS  <  20
who  changed  to  dutasteride  monotherapy,  switched  without
noticeable  deterioration  in  their  symptoms.16 Of  the  men
with  severe  baseline  symptoms  who  switched  to  dutasteride
monotherapy,  34%  reported  a  worsening  of  their  symptoms
compared  with  20%  in  the  group  that  continued  to  receive
combination  therapy.16 The  optimal  duration  of  combination
therapy  before  -blocker  discontinuation  has  not  yet  been
determined.12
PDE5I/-blocker combination therapy
Three  main  PDE5Is  have  been  used  for  some  time  for
the  treatment  of  erectile  dysfunction  on  an  on-demand
dosing  schedule:  tadalaﬁl,17 sildenaﬁl,18 and  vardenaﬁl.19
Sildenaﬁl  and  vardenaﬁl  are  similar  agents  in  terms  of
their  pharmacokinetic  proﬁles,  with  a  short  time  to  maxi-
mum  plasma  concentration  (1  hour)  and  elimination  half-life
(4--5  hours).20 In  comparison,  tadalaﬁl  has  a  similar  time  to
maximum  plasma  concentration  (2  hours)  although  markedly
lower  systemic  clearance  relative  to  other  PDE5Is,  with  a
half-life  of  17.5  hours,  making  it  suitable  for  QD  use.21 The
positive  results  of  the  tadalaﬁl  monotherapy  QD  registration
trial  may  have  led  to  the  current  interest  in  the  use  of  PDE5Is
as  part  of  combination  therapy.
The  primary  international  clinical  trial  of  tadalaﬁl
5  mg  QD  monotherapy  against  an  active  control  compared
tadalaﬁl  with  placebo  and  tamsulosin  0.4  mg  QD  in  511  men
with  LUTS/BPH,  IPSS  ≥  13,  and  Qmax ≥  4  to  ≤15  mL/s  over  a
12-week  treatment  period.22 Oelke  et  al.  reported  statisti-
cally  signiﬁcant  improvements  in  total  IPSS  from  the  baseline
to  week  12  for  both  tadalaﬁl  (LS  mean  ±  SE:  −2.1  ±  0.6;
p  =  0.001)  and  tamsulosin  (−1.5  ±  0.6;  p  =  0.023)  compared
with  placebo.  The  IPSS  change  from  the  baseline  was
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6.3  ±  0.5  in  the  tadalaﬁl  group  and  −5.7  ±  0.5  in  the  tam-
ulosin  group.  No  direct  comparison  between  tadalaﬁl  and
amsulosin  was  reported.  Qmax increased  signiﬁcantly  versus
lacebo  with  both  tadalaﬁl  (2.4  mL/s;  p  =  0.009)  and  tam-
ulosin  (2.2  mL/s;  p  =  0.014).22 In  sexually  active  men  with
rectile  dysfunction,  erectile  function  also  showed  signiﬁ-
ant  improvement  with  tadalaﬁl  (change  in  the  International
ndex  of  Erectile  Function  [IIEF]  score  4.0;  p  < 0.001),  but
ot  with  tamsulosin,  compared  with  placebo.  The  authors
oncluded  that  tadalaﬁl  and  tamsulosin  once-daily  resulted
n  signiﬁcant  and  numerically  similar  improvements  versus
lacebo  in  LUTS/BPH  and  Qmax.22 In  another  study,  Egerdie
t  al.  investigated  two  doses  of  tadalaﬁl  (2.5  and  5  mg)  in  a
lacebo-controlled  trial  in  sexually  active  men  with  erectile
ysfunction  and  BPH/LUTS,  and  found  signiﬁcant  improve-
ents  in  IPSS  with  the  5  mg  dose  (LS  mean  −4.6;  p  <  0.001)
nd  in  IEFF  Erectile  Function  Domain  (IIEF-EF)  scores  versus
lacebo  with  both  tadalaﬁl  doses  (both  p  <  0.001).23 Tadalaﬁl
 mg  has  been  licensed  since  2011  for  once-daily  use  in  the
reatment  of  BPH  with  or  without  erectile  dysfunction.
rossover  safety  studies  of  PDE5Is  as  add-on
herapy
 number  of  initial  crossover  studies  were  performed  to
nvestigate  the  safety  of  the  PDE5I/-blocker  treatment
ombination,  although  they  primarily  focused  on  the  inter-
ittent  addition  of  a  PDE5I  to  a  regular  -blocker  regimen
or  improvement  of  erectile  dysfunction.  These  studies
ere  designed  with  the  principal  aim  of  detecting  any
otential  hemodynamic  effects  of  the  treatment  combi-
ation.  A  crossover  study,  with  18  patients  in  each  arm,
as  performed  to  investigate  the  potential  hemodynamic
nteractions  of  two  doses  of  tadalaﬁl  (10  and  20  mg  QD)  in
ombination  with  either  doxazosin  8  mg  QD  or  tamsulosin
.4  mg  QD.24 The  study  reported  that  tadalaﬁl  augmented
he  hypotensive  effects  of  doxazosin,  but  had  little  hemody-
amic  interaction  with  tamsulosin.  Another  crossover  study
ssessed  the  pharmacodynamic  effects  of  two  doses  of  coad-
inistered  vardenaﬁl  (10  mg  or  20  mg  QD)  in  patients  with
PH  undergoing  stable  tamsulosin  therapy  (0.4  or  0.8  mg
D).  No  evidence  of  clinically  signiﬁcant  hypotension  was
bserved,  and  no  patient  exhibited  symptomatic  hypoten-
ion  (systolic  blood  pressure  <85  mmHg  with  dizziness).25 A
hird  crossover  study  investigating  alfuzosin  10  mg  QD  with
 single  dose  of  tadalaﬁl  20  mg  QD  detected  no  clinically
elevant  interactions.26 The  combination  therapy  elicited  a
aximal  decrease  in  standing  systolic  blood  pressure  (mean
ifference  4.35  mmHg)  that  was  not  signiﬁcantly  different
rom  placebo.
The  hemodynamic  effects  of  tamsulosin  0.4  mg  QD  and
ildenaﬁl  100  mg  QD  combination  therapy  were  investigated
n  16  patients  with  BPE.27 Both  the  sildenaﬁl  monotherapy
−11  ±  2  mmHg  [mean  ±  standard  error  of  the  mean])  and
ildenaﬁl/tamsulosin  combination  therapy  (−14  ±  2  mmHg)
roups  experienced  decreased  supine  systolic  arterial  blood
ressure  compared  with  placebo  (−2  ±  4  mmHg;  p  <  0.05).
eart  rate,  diastolic  arterial  pressure,  stroke  index,  cardiac
ndex,  and  arterial  pulse  wave  velocity  were  not  signiﬁ-
antly  affected  by  any  of  the  treatments  compared  with
lacebo.27 Another  crossover  study  investigated  the  effects
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f  the  doxazosin  gastrointestinal  therapeutic  system  with
ardenaﬁl  10  mg  QD  on  the  hemodynamic  status  of  37
atients  with  BPH  and  erectile  dysfunction.28 The  combi-
ation  therapy  was  associated  with  a  maximum  decrease
n  standing  systolic  blood  pressure  of  6.18  mmHg  (p  =  0.039
ersus  placebo).  One  patient  had  an  asymptomatic  stand-
ng  systolic  blood  pressure  <85  mmHg,  but  otherwise,  no
ymptomatic  hypotension  or  clinically  signiﬁcant  adverse
ardiovascular  events  were  reported  during  the  study.28
More  recently,  a  larger  study  was  performed  to  investi-
ate  the  safety  of  the  daily  coadministration  of  -blockers
ith  tadalaﬁl  in  318  men  with  LUTS  secondary  to  BPH.
ligible  men  ≥45  years  receiving  stable  -blocker  therapy
uroselective:  alfuzosin,  silodosin,  and  tamsulosin;  non-
roselective:  doxazosin  and  terazosin)  were  randomized
o  tadalaﬁl  5  mg  QD  or  placebo  for  12  weeks.29 There
as  no  signiﬁcant  difference  in  the  proportion  of  men
ho  reported  treatment-emergent  dizziness  (tadalaﬁl/-
locker  7.0%;  placebo/-blocker  5.7%;  p  =  0.403).  A  trend
as  seen  for  increased  hemodynamic  signs  and  symptoms  in
en  taking  non-uroselective  -blockers,  particularly  doxa-
osin,  although  this  association  was  not  detected  with  the
ther  -blocker  combinations.29 The  pilot  studies  testing
-blocker  therapy  with  both  intermittent  and  continuous
DE5I  treatment  report  that  the  treatment  combination
s  safe,  with  minor  hemodynamic  changes  not  considered
linically  relevant.24--28
rospective  combination  therapy  studies
 recent  meta-analysis  of  ﬁve  trials  that  tested  PDE5Is  in
ombination  with  -blockers  in  437  patients  (264  in  the
ombination  group  and  173  in  the  PDE5I  group)  found  signiﬁ-
antly  lower  IPSS  scores  in  the  combination  group  than  in  the
ontrol  group  (pooled  estimate  −4.21;  95%  CI  −7.09  to  1.32;
 =  0.004).30 The  same  meta-analysis  examined  the  effect
f  combination  therapy  versus  PDE5I  monotherapy  on  Qmax
cross  four  studies  involving  204  patients,  reporting  a  statis-
ically  signiﬁcant  improvement  in  Qmax in  the  combination
roup  compared  with  the  control  group  (pooled  estimate
.43;  95%  CI  0.38--2.47;  p  =  0.007).30
adalaﬁl  treatment  combinations
amsulosin  is  the  most  studied  -blocker  in  combination  with
adalaﬁl.  In  a  crossover  pilot  study,  Bechara  et  al.  compared
amsulosin  0.4  mg  QD  with  and  without  tadalaﬁl  20  mg  QD  in
7  patients  with  a  history  of  BPH/LUTS;  patients  received
ach  treatment  regimen  for  45  days.31 Improvements  from
he  baseline  in  the  IPSS  score  and  IPSS-quality  of  life  (QOL)
ere  signiﬁcant  in  both  treatment  groups  (p  <  0.001  for
oth),  although  the  IPSS  mean  change  from  the  baseline  was
igniﬁcantly  larger  in  the  combination  group  compared  with
he  tamsulosin  group  (−9.2  vs.  −6.7;  p  <  0.05).  Improve-
ents  in  Qmax and  decreases  in  post-void  residual  (PVR)
olume  from  the  baseline  were  similar  in  both  treatment
roups.  The  IEFF-EF  showed  signiﬁcant  improvement  only  in
he  combination  group  (p  <  0.001)  and  the  global  assessment
uality  showed  that  all  patients  preferred  the  combination
cheme.  During  the  study,  two  adverse  event-related  discon-
inuations  occurred,  one  with  headache  (combination  group)
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nd  the  other  with  moderate  cutaneous  rash  (tamsulosin
roup).  No  serious  adverse  events  (SAE)  were  reported.31
Regadas  et  al.  performed  urodynamic  studies  to
ompare  tadalaﬁl  5  mg/tamsulosin  0.4  mg  QD  with
lacebo/tamsulosin  0.4  mg  QD  in  40  patients  with  LUTS
econdary  to  BPH.32 At  the  end  of  the  30-day  study  period,
he  primary  endpoint,  detrusor  pressure  at  maximum
ow,  was  signiﬁcantly  reduced  in  the  tadalaﬁl/tamsulosin
roup  (13  ±  17.0)  compared  with  the  placebo/tamsulosin
roup  (−1.2  ±  14.4;  p  =  0.03).  Similarly,  total  IPSS,  and
he  storage  and  voiding  subscores  improved  signiﬁcantly
n  the  tadalaﬁl/tamsulosin  group  compared  with  the
lacebo/tamsulosin  group  (p  ≤  0.05  for  all).32
In  a  larger  study  of  133  patients  with  LUTS  due  to  BPH,
ingh  et  al.  compared  tadalaﬁl  10  mg/tamsulosin  0.4  mg
D  combination  therapy  with  tadalaﬁl  10  mg  QD  monother-
py  and  tamsulosin  0.4  mg  QD  monotherapy.33 At  the  end
f  the  3-month  study  period,  signiﬁcant  improvement  in
he  IPSS  score  was  reported  across  all  treatment  groups
tamsulosin:  −50.9%,  p  <  0.05;  tadalaﬁl:  −33.5%,  p  <  0.05;
adalaﬁl/tamsulosin  combination:  −53.9%,  p  <  0.05).  Simi-
arly,  signiﬁcant  improvements  in  the  IIEF-5  score,  Qmax,
VR  volume,  and  QOL  were  reported  in  the  three  treatment
roups.  In  the  tamsulosin,  tadalaﬁl  and  tamsulosin/tadalaﬁl
ombination  groups,  the  IIEF-5  score  increased  [+39.3%
p  <  0.05),  +46.0%  (p  <  0.05),  and  +60.2%  (p  <  0.05),  respec-
ively];  Qmax increased  [+34.0%  (p  <  0.05),  +29.8%  (p  <  0.05),
nd  +37.0%  (p  <  0.05),  respectively];  PVR  volume  was
educed  [−60.9%  (p  <  0.05),  −49.5%  (p  <  0.05),  and  −63.0%
p  <  0.05),  respectively];  and  QOL  scores  also  improved  sig-
iﬁcantly  [−73.4%  (p  <  0.05),  −70.3%  (p  <  0.05),  and  −79.7%
p  <  0.05),  respectively].33 Five  adverse  event-related  treat-
ent  discontinuations  (3.7%)  occurred  during  the  study,  but
here  were  no  severe  adverse  events  or  SAEs.  Adverse  events
eading  to  discontinuation  were  worsening  of  LUTS  (tadalaﬁl
onotherapy),  severe  myalgia  and  backache  (one  each  in
he  tadalaﬁl  monotherapy  and  tadalaﬁl/tamsulosin  groups),
ushing,  headache,  myalgia,  and  hypotension  (tadalaﬁl
onotherapy),  and  an  increase  in  intraocular  pressure  in
 patient  previously  diagnosed  with  glaucoma  (tadalaﬁl
onotherapy).33
ildenaﬁl  treatment  combinations
he  efﬁcacy  of  combination  therapy  with  sildenaﬁl  25  mg
D  and  alfuzosin  10  mg  QD  was  investigated  by  Kaplan
t  al.  in  a  pilot  study  of  62  men  with  LUTS  suggestive  of
PH  and  erectile  dysfunction.34 Improvements  in  the  IPSS
ere  signiﬁcant  across  the  three  treatment  groups,  although
hey  were  greatest  in  the  men  receiving  the  combination
herapy  (−24.1%)  compared  with  alfuzosin  (−15.6%)  or  sil-
enaﬁl  alone  (−16.9%;  p  <  0.03).  Frequency,  nocturia,  PVR
olume,  and  Qmax were  signiﬁcantly  improved  with  both
lfuzosin  monotherapy  and  the  combination  treatment,  and
mprovement  in  the  IIEF  was  marked  with  sildenaﬁl  (49.7%),
lthough  greater  with  the  combination  treatment  (58.6%).
he  rate  of  adverse  event-related  treatment  discontinua-
ion  was  11%  overall  (seven  patients:  two  in  the  alfuzosin
roup  [dizziness],  two  in  the  sildenaﬁl  group  [ﬂushing  and
yspepsia],  and  three  in  the  combination  group  [dizziness;
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tCombination  therapy  for  treatment  of  lower  urinary  tract  sy
gastric  upset]).  No  SAEs  or  evidence  of  hypotension  or  syn-
cope  occurred  during  the  12-week  treatment  period.34
An  8-week  study  comparing  sildenaﬁl  citrate  25  mg  four
times/week  monotherapy  with  tamsulosin  0.4  mg  QD  or  the
combination  of  these  agents  in  60  men  with  LUTS  sugges-
tive  of  BPH  and  erectile  dysfunction  was  reported  in  2010.35
The  IPSS,  Qmax,  PVR  volume,  Sexual  Health  Inventory  of  Male
(SHIM)  scores,  and  the  third  and  fourth  questions  on  the  IIEF
(relating  to  achieving  and  sustaining  penetration,  respec-
tively)  were  signiﬁcantly  improved  in  all  treatment  groups
compared  with  the  baseline  (p  <  0.001  for  all).  Improvement
in  IPSS  was  greater  in  the  combination  group  (40.1%)  and
tamsulosin  group  (36.2%)  compared  with  the  sildenaﬁl  group
(28.2%;  p  <  0.001).  Similarly,  PVR  volume  reductions  were
also  signiﬁcantly  greater  in  the  combination  and  tamsulosin
monotherapy  groups  compared  with  sildenaﬁl  monotherapy
(p  <  0.001  for  both).  Improvement  in  Qmax was  signiﬁcantly
higher  in  the  combination  therapy  group  (42.0%)  compared
with  either  of  the  monotherapy  groups  (p  <  0.001).  Tuncel
et  al.  concluded  that  the  combination  treatment  of  silden-
aﬁl/tamsulosin  was  not  superior  to  tamsulosin  monotherapy
in  improving  voiding  symptoms.35
Vardenaﬁl  treatment  combinations
Gacci  et  al.  compared  the  safety  and  efﬁcacy  of  tamsulosin
0.4  mg/placebo  QD  with  tamsulosin  0.4  mg/vardenaﬁl  10  mg
QD  combination  therapy  in  60  men  with  persistent  storage
LUTS  after  a  2-week  run-in  period  with  tamsulosin.36 Sig-
niﬁcant  improvements  compared  with  the  baseline  in  the
Qmax,  average  ﬂow  rate  (Qave),  irritative-IPSS  subscores,  and
the  IIEF  were  reported  with  the  combination  therapy  over
tamsulosin  monotherapy  (p  ≤  0.039  for  all)  at  the  12-week
follow-up.  No  differences  in  the  incidence  of  common,
treatment-related  adverse  events  were  found  between  the
groups,  and  no  patient  reported  any  SAEs.36
Clinical  management  implications
The  combination  of  -blocker  and  PDE5I  has  been  shown  in
recent  studies  to  be  more  effective  than  PDE5I  monotherapy
for  managing  erectile  dysfunction  in  men  with  LUTS/BPH.
Considering  that  43.0%  to  82.5%  of  patients  suffering  LUTS
also  experience  erectile  dysfunction,3 this  treatment  com-
bination  holds  much  promise,  particularly  in  patients  who
have  shown  a  poor  response  to  monotherapy  with  either
of  these  classes  of  agent.  The  PDE5I/-blocker  combination
therapy  has  been  shown  to  improve  Qmax,  PVR  volume,  and
detrusor  pressure  at  maximum  ﬂow  compared  with  placebo,
and  also  results  in  additive  effects  with  respect  to  the  IEFF
and  IPSS  compared  with  PDE5I  or  -blocker  monotherapy.
The  mechanism  for  the  additive  improvement  in  symptoms
produced  with  combination  therapy  is  not  yet  fully  eluci-
dated.  It  has  been  hypothesized  that  the  agents  work  via
two  distinct  mechanisms  of  action,  but  on  common  target
organs.33
Since  both  -blockers  and  PDE5Is  have  vasodilatory
effects,  there  has  been  particular  interest  in  determining
whether  an  additive  decrease  in  blood  pressure  exists  with
combination  treatment.  As  described,  the  primary  objective
of  the  trial  reported  by  Goldﬁscher  et  al.  was  to  investigate
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he  potential  hemodynamic  effects  of  daily  coadministra-
ion  of  tadalaﬁl  5  mg  with  various  -blockers  over  a  12-week
reatment  period.29 The  changes  in  hemodynamic  signs  and
ymptoms  were  similar  in  men  receiving  tadalaﬁl  or  placebo
n  combination  with  an  -blocker,  and  no  cases  of  syn-
ope  or  SAEs  attributable  to  hypotension  were  reported.
lthough  the  study  was  not  powered  for  subgroup  analy-
is,  when  stratiﬁed  by  -blocker  type,  a trend  was  observed
or  increased  hemodynamic  signs  and  symptoms  in  men  tak-
ng  non-uroselective  -blockers,  particularly  doxazosin.  This
as  not  seen  with  the  coadministration  of  uroselective  -
lockers,  such  as  alfuzosin,  silodosin,  and  tamsulosin.29 More
enerally,  across  the  studies  investigating  PDE5I/-blocker
oadministration,  no  new  safety  signals  were  detected,  with
iscontinuations  due  primarily  to  the  adverse  events  of
yalgia,  dizziness,  sensation  of  heaviness,  and  headache.
o  SAEs  were  reported  in  these  clinical  trials.
DE5I/5-ARI combination therapy
he  use  of  a  PDE5I  together  with  a 5-ARI  has  been  sug-
ested  to  offer  earlier  symptomatic  relief  in  LUTS  than
ith  5-ARIs  alone,  and  it  also  seems  that  the  PDE5I  may
educe  the  sexual  side  effects  associated  with  5-ARI  use,
ncluding  erectile  dysfunction,  decreased/lost  libido,  and
jaculation  delay/failure.  In  a  recent  study  investigating  the
oadministration  of  tadalaﬁl  5  mg  QD  and  ﬁnasteride  5  mg
D,  350  5-ARI-naïve  men  with  IPSS  ≥  13  and  LUTS  secondary
o  BPH  were  treated  with  placebo/ﬁnasteride  and  345  with
adalaﬁl/ﬁnasteride  for  26  weeks.37 Least  squares  mean
hanges  from  the  IPSS  baseline  after  4,  12,  and  26  weeks  of
ombination  therapy  were  −4.0,  −5.2,  and  −5.5,  respec-
ively,  and  represented  signiﬁcantly  greater  changes  from
he  baseline  than  the  placebo/ﬁnasteride  group  at  all  visits
p  ≤  0.022)  (Fig.  1).  The  IPSS  subscores  for  storage  and  void-
ng  and  the  QOL  index  were  numerically  improved  with  the
ombination  treatment,  although  there  was  no  statistically
igniﬁcant  difference.  Least  squares  mean  changes  from  the
aseline  in  erectile  function,  measured  as  the  IIEF-EF  score,
ere  3.7  after  4  weeks  and  4.7  after  12  and  26  weeks  of
ombination  therapy,  while  the  corresponding  scores  with
lacebo/ﬁnasteride  were  −1.1,  0.6,  and  −0.0  (p  <  0.001  at
ll  visits).37
The  overall  safety  proﬁle  did  not  deviate  from  that
reviously  established  for  tadalaﬁl  or  ﬁnasteride  monother-
py.  Most  treatment-emergent  adverse  events  were  mild
o  moderate  in  severity,  and  the  incidence  of  SAEs
nd  discontinuations  related  to  adverse  events  was  low
nd  showed  no  signiﬁcant  difference  between  treatment
roups.  Fewer  patients  receiving  combination  therapy
eported  reduced  libido  or  erectile  dysfunction  com-
ared  with  those  in  the  placebo/ﬁnasteride  group:  ﬁve
atients  in  the  placebo/ﬁnasteride  group  and  one  patient
n  the  tadalaﬁl/ﬁnasteride  group  reported  erectile  dys-
unction.  Five  patients  reported  decreased  or  lost  libido
nd  two  patients  reported  ejaculation  delay/failure  in
he  placebo/ﬁnasteride  group,  while  no  patients  in  the
adalaﬁl/ﬁnasteride  group  reported  decreased/lost  libido  or
dverse  ejaculation  issues.37
Given  that  LUTS  improvements  are  generally  observed
fter  6--12  months  of  5-ARI  monotherapy,  it  would  be
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Figure  1  LS  mean  change  from  the  baseline  in  the  Interna-
tional Prostate  Symptom  Score  (IPSS)  total  score  over  a  26-week
treatment  period  in  patients  who  were  randomized  to  the
study treatment  and  received  ≥1  dose  of  the  double-blind
study  drug  (TAD/FIN  345  and  PBO/FIN  345).  Results  adapted
from Casabé  et  al.,  2014.37 *  p  ≤  0.001.  Error  bars  repre-
sent standard  error.  Abbreviations:  IPSS,  International  Prostate
Symptom  Score;  LS,  least  squares;  LSTD,  least  squares  treat-
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went difference;  PBO/FIN,  placebo/ﬁnasteride  5  mg  once  daily;
AD/FIN,  tadalaﬁl  5  mg  +  ﬁnasteride  5  mg  once  daily.
orthwhile  to  investigate  this  treatment  combination  in
 longer-term  study  with  treatment  duration  of  at  least
2  months.6,38,39 Although  the  generalizability  of  these  ﬁnd-
ngs  is  limited  to  men  with  IPSS  ≥  13  and  large  prostate
olumes  (≥30  mL),  this  category  of  combination  therapy  is
ery  appealing  in  managing  BPH/LUTS  symptoms  in  patients
ith  the  potential  for  disease  progression  who  wish  to  main-
ain  or  improve  sexual  function.
-Blocker/antimuscarinic combination therapy
raditionally,  -blockers  have  been  used  to  manage  LUTS
ssociated  with  BPH  and  antimuscarinics  used  for  OAB,
ut  we  now  have  increasing  data  on  the  combination  of
hese  agents.  The  majority  of  studies  investigating  this
ombination  have  looked  at  antimuscarinics  as  add-on
o  baseline  -blocker  therapy:  studies  have  investigated
amsulosin  with  add-on  solifenacin,40,41 propiverine,42 and
xybutynin,43 -blockers  with  add-on  tolterodine,44 or
ropiverine  extended-release.45
The  two  main  studies  that  prospectively  assigned  com-
ination  treatment  with  an  -blocker  and  antimuscarinic
ave  shown  improvements  over  monotherapy,  particularly
egarding  storage  symptoms.  An  8-week  study  comparing
oxazosin  4  mg  QD  controlled-release  gastrointestinal  ther-
peutic  system  with  and  without  propiverine  hydrochloride
0  mg  QD  in  211  men  with  OAB  and  BPO  reported  signiﬁcant
eneﬁts  in  urinary  frequency,  average  micturition  volume,
torage,  urgency,  and  patient  satisfaction  in  the  combi-
ation  group  (p  <  0.029  for  all).46 Improvement  in  voiding
ymptoms  was  similar  in  the  two  groups,  but  improve-
ent  in  storage  symptoms  was  signiﬁcantly  higher  in  the
ombination  therapy  group  (p  =  0.029).  This  was  accom-
anied  by  higher  overall  adverse  event  rates,  although
a
o

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imilar  discontinuation-  and  adverse  event-related  discon-
inuation  rates  were  observed  between  treatment  groups.46
he  TIMES  study  was  a  4-arm  prospective  study  that  com-
ared  12  weeks  of  treatment  with  placebo,  tolterodine  4  mg
D  extended-release,  tamsulosin  0.4  mg  QD,  and  toltero-
ine  4  mg  extended-release/tamsulosin  0.4  mg  combination
herapy  in  879  men  with  OAB  and  BPH.47 Men  with  clinically
igniﬁcant  bladder  outlet  obstruction  (PVR  volume  >  200  mL
nd  Qmax <  5  mL/s)  or  PSA  >  10  ng/mL  with  a  risk  for  prostate
ancer  were  excluded  from  the  study.  A  total  of  80%  of
en  receiving  combination  therapy  reported  treatment  ben-
ﬁt  by  week  12  compared  with  62%  receiving  placebo,  71%
eceiving  tamsulosin,  and  65%  receiving  tolterodine.  Only
he  combination  therapy  resulted  in  a  signiﬁcant  improve-
ent  in  quality  of  life  and  total  IPSS  compared  with  placebo
p  =  0.03  for  both).  The  most  commonly  occurring  adverse
vent  was  dry  mouth,  with  two  and  ﬁve  patients  discon-
inuing  treatment  due  to  dry  mouth  in  the  tamsulosin  and
ombination  therapy  groups,  respectively.  The  incidence  of
UR  requiring  catheterization  was  low  (combination  treat-
ent  0.4%,  tolterodine  0.4%,  and  0%  in  the  other  groups).47
Two  more  recent  studies  investigated  solife-
acin/tamsulosin  combination  therapy.48,49 Kaplan  et  al.
ompared  two  doses  of  solifenacin  (6  mg  and  9  mg  QD)  with
he  tamsulosin  0.4  mg  QD  oral  controlled  absorption  system
ombination  versus  placebo  for  12  weeks  in  a  safety  study.
his  study  focused  on  the  outcomes  of  Qmax and  detrusor
ressure  at  Qmax and  both  were  reported  to  be  non-inferior
o  placebo  in  each  of  the  interventional  groups.48 Urinary
etention  was  reported  in  one  patient,  who  was  receiv-
ng  combination  therapy  (lower  dose  solifenacin).  Since
rostate  size  and  PSA  levels  were  not  measured  in  this
tudy,  the  generalizability  of  these  results  is  limited.48 In
he  NEPTUNE  study,  1334  men  with  storage  and  voiding  LUTS
ere  randomized  to  one  of  four  treatment  arms:  placebo,
amsulosin  0.4  mg  QD  oral  controlled  absorption  system
TOCAS),  solifenacin  6  mg  QD  plus  TOCAS,  or  solifenacin
 mg  QD  plus  TOCAS  for  12  weeks.49 Reductions  in  the
PSS  and  total  urgency  and  frequency  score  were  reported
n  all  treatment  arms,  with  solifenacin  6  mg  plus  TOCAS
igniﬁcantly  improving  storage  symptoms  compared  with
lacebo  (p  <  0.001)  and  TOCAS  monotherapy  (p  <  0.01)  and
igniﬁcantly  improving  voiding  symptoms  compared  with
lacebo  (p  ≤  0.05).  Urinary  retention  occurred  in  eight
atients  during  the  study  (seven  cases  were  considered
rug-related  and  ﬁve  cases  required  catheterization:  one
ase  with  TOCAS  [0.3%]  and  one  with  solifenacin  6  mg  plus
OCAS  [0.3%]  and  three  cases  with  solifenacin  9  mg  plus
OCAS  [0.9%]).49
Although  all  of  the  prospective  studies  investigating  the
-blocker/antimuscarinic  combination  have  been  short  in
uration  (8--12  weeks),  the  ﬁndings  of  these  studies  conﬁrm
hat  the  short-term  combination  therapy  response  rates  are
mproved  compared  with  monotherapy  in  men  with  mod-
rate  to  severe  storage  and  voiding  symptoms.  As  such,
his  combination  may  represent  a  good  treatment  alterna-
ive  for  patients  who  have  not  responded  to  monotherapy
ith  an  -blocker  or  antimuscarinic  drug.  This  treatment
pproach  is  supported  in  clinical  guidelines,  which  rec-
mmend  offering  antimuscarinics  to  men  with  OAB,  and
-blocker/antimuscarinic  combination  treatment  for  those
ith  persisting  storage  symptoms.50
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Conclusions
The  evidence  base  supporting  the  coadministration  of  two
agents  for  the  clinical  management  of  LUTS  is  expanding.
Although  -blockers  are  traditionally  the  ﬁrst-line  treat-
ment  option  for  patients  with  voiding  symptoms,  PDE5Is
were  recently  shown  to  have  similar  efﬁcacy  in  improving
IPSS  and  Qmax. The  combination  of  these  classes  of  agents
was  found  to  be  more  effective  than  either  of  the  monother-
apies  for  providing  symptomatic  relief  (as  assessed  by  the
IPSS  and  IEFF)  and  particularly  effective  in  resolving  erectile
dysfunction.  Investigations  of  hemodynamic  changes  with
this  treatment  combination  showed  similar  changes  with
tadalaﬁl/-blocker  therapy  compared  with  placebo/-
blocker  therapy,  with  a  trend  for  increased  hemodynamic
signs  only  with  non-uroselective  -blockers,  most  notably
doxazosin.  No  new  safety  signals  were  detected  with  this
treatment  combination.24--28,31--34,36,51
Antimuscarinic  agents  remain  the  ﬁrst-line  treatment  for
patients  with  moderate  to  severe  storage  symptoms  and
OAB,  although  the  addition  of  an  -blocker  may  further
improve  storage  and  voiding  symptoms  in  those  men  who
have  not  responded  to  antimuscarinic  monotherapy,  and  is
supported  by  clinical  treatment  guidelines.50 Longer-term
studies  assessing  the  efﬁcacy  of  this  treatment  combination
would  add  to  the  existing  evidence  showing  improvement
with  8  to  12-week  treatment  duration.46--49
5-ARIs  are  the  mainstay  of  treatment  for  patients  at
risk  for  LUTS  clinical  progression,  and  there  is  a  wealth  of
evidence  for  the  concomitant  use  of  -blockers  in  older
men  and/or  those  with  large  prostates.7--9 The  optimal
treatment  duration  before  -blocker  discontinuation  has
not  yet  been  determined,  although  the  results  of  two
studies  indicate  that  discontinuation  may  only  be  suitable
for  patients  with  mild  to  moderate  symptoms,  as  many  of
those  with  severe  baseline  symptoms  deteriorated  after
-blocker  withdrawal.14,16 The  use  of  PDE5Is  in  combination
with  5-ARIs  in  a  similar  patient  population  at  risk  for  clinical
progression  has  been  the  subject  of  recent  investigation,
which  has  shown  it  offers  early  symptomatic  relief  and  also
reduces  the  sexual  side  effects  associated  with  5-ARI  use.37
This  treatment  combination  warrants  further  investigation
through  large-scale  clinical  trials  with  treatment  duration
of  at  least  6--12  months.
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